



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

HH

JUL 18 1997

Stephen G. Kunin
Deputy Assistant Commissioner for
Patent Policy and Projects
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, D.C. 20231

RECEIVED
JUL 25 1997
PATENT EXTENSION
A/C PATENTS

Re: ALDARA™
Docket No. 97E-0269

Dear Mr. Kunin:

This is in regard to the application for patent term extension for U.S. Patent No. 5,238,944 filed by Riker Laboratories under 35 U.S.C. § 156. The human drug product identified in the patent extension application is ALDARA™ (Imiquimod), which was assigned New Drug Application (NDA) No. 20-723.


A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp 1224 (E.D. Va. 1989), aff'd, 894 F. 2d 392 (Fed. Cir. 1990).

The NDA was approved on February 27, 1997, which makes the submission of the patent term extension application on April 24, 1997, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely,


Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Ted K. Ringsred
3M/Office of Intellectual Property Counsel
P.O. Box 33427
St. Paul, MN 55133-3427